{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:01:12Z","timestamp":1791594072873,"version":"4.3.4"},"reference-count":179,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in 5 prototypic autoimmune diseases: systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis, primary Sj\u00f6gren syndrome, and systemic sclerosis. We will also discuss current therapeutic strategies that directly or indirectly target the IFN-I system.<\/jats:p>","DOI":"10.3899\/jrheum.2022-0827","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T08:20:14Z","timestamp":1688199614000},"page":"1103-1113","source":"Crossref","is-referenced-by-count":65,"title":["Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response"],"prefix":"10.3899","volume":"50","author":[{"given":"Ana Carolina","family":"Londe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0759-5222","authenticated-orcid":false,"given":"Ruth","family":"Fernandez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Rog\u00e9rio","family":"Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Niewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"2023090107351014000_50.9.1103.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78088"},{"key":"2023090107351014000_50.9.1103.2","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/rheumatology\/keab448","article-title":"Precision medicine in autoimmune diseases: fact or fiction","volume":"60","author":"Toro-Dom\u00ednguez","year":"2021","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I interferons in autoimmunity","volume":"142","author":"Fernandez-Ruiz","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2023090107351014000_50.9.1103.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm1590"},{"key":"2023090107351014000_50.9.1103.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.03.012"},{"key":"2023090107351014000_50.9.1103.6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052331"},{"key":"2023090107351014000_50.9.1103.7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-021-00554-y","article-title":"Cytosolic DNA sensing by cGAS: regulation, function, and human diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2023090107351014000_50.9.1103.8","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2012.719953"},{"key":"2023090107351014000_50.9.1103.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.027"},{"key":"2023090107351014000_50.9.1103.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3296"},{"key":"2023090107351014000_50.9.1103.11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151876"},{"key":"2023090107351014000_50.9.1103.12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800221"},{"key":"2023090107351014000_50.9.1103.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04642-z"},{"key":"2023090107351014000_50.9.1103.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001337107"},{"key":"2023090107351014000_50.9.1103.15","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311425522"},{"key":"2023090107351014000_50.9.1103.16","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1038\/srep03792","article-title":"Genetic variations in toll-like receptors (TLRs 3\/7\/8) are associated with systemic lupus erythematosus in a Taiwanese population","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"2023090107351014000_50.9.1103.17","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/art.42416","article-title":"De novo PACSIN1 gene variant found in childhood lupus reveals a role for PACSIN1-TRAF4 complex in TLR7 activation","volume":"75","author":"Xie","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2792"},{"key":"2023090107351014000_50.9.1103.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701266104"},{"key":"2023090107351014000_50.9.1103.20","doi-asserted-by":"publisher","DOI":"10.1038\/ng.565"},{"key":"2023090107351014000_50.9.1103.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24885"},{"key":"2023090107351014000_50.9.1103.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200901"},{"key":"2023090107351014000_50.9.1103.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.30193"},{"key":"2023090107351014000_50.9.1103.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200275"},{"key":"2023090107351014000_50.9.1103.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002178"},{"key":"2023090107351014000_50.9.1103.26","doi-asserted-by":"publisher","DOI":"10.1038\/ng1782"},{"key":"2023090107351014000_50.9.1103.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23142"},{"key":"2023090107351014000_50.9.1103.28","doi-asserted-by":"crossref","first-page":"e110044","DOI":"10.1371\/journal.pone.0110044","article-title":"Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis\/dermatomyositis in Chinese Han population","volume":"9","author":"Chen","year":"2014","journal-title":"PLOS ONE"},{"key":"2023090107351014000_50.9.1103.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00982.x"},{"key":"2023090107351014000_50.9.1103.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.24600"},{"key":"2023090107351014000_50.9.1103.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.34571"},{"key":"2023090107351014000_50.9.1103.32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.39504","article-title":"Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture","volume":"68","author":"Alarc\u00f3n-Riquelme","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.33","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat Commun"},{"key":"2023090107351014000_50.9.1103.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.27182"},{"key":"2023090107351014000_50.9.1103.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200463"},{"key":"2023090107351014000_50.9.1103.36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41467-022-29514-y","article-title":"Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat Commun"},{"key":"2023090107351014000_50.9.1103.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.34"},{"key":"2023090107351014000_50.9.1103.38","doi-asserted-by":"publisher","DOI":"10.1038\/ng.81"},{"key":"2023090107351014000_50.9.1103.39","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn184"},{"key":"2023090107351014000_50.9.1103.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073003"},{"key":"2023090107351014000_50.9.1103.41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humimm.2013.04.034","article-title":"Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody","volume":"74","author":"Zheng","year":"2013","journal-title":"Hum Immunol"},{"key":"2023090107351014000_50.9.1103.42","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp119"},{"key":"2023090107351014000_50.9.1103.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.24688"},{"key":"2023090107351014000_50.9.1103.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.24958"},{"key":"2023090107351014000_50.9.1103.45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/art.41929","article-title":"Contribution of rare genetic variation to disease susceptibility in a large Scandinavian myositis cohort","volume":"74","author":"Bianchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.46","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"2023090107351014000_50.9.1103.47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/acr2.11073","article-title":"Type I interferon predicts an alternate immune system phenotype in systemic lupus erythematosus","volume":"1","author":"Thanarajasingam","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2023090107351014000_50.9.1103.48","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948129"},{"key":"2023090107351014000_50.9.1103.49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.immuni.2016.12.014","article-title":"Follicular dendritic cell activation by TLR ligands promotes autoreactive B cell responses","volume":"46","author":"Das","year":"2017","journal-title":"Immunity"},{"key":"2023090107351014000_50.9.1103.50","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.39987","article-title":"Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective Type I interferon in mouse skin by recruited inflammatory monocytes","volume":"69","author":"Sontheimer","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav4011"},{"key":"2023090107351014000_50.9.1103.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.07.021"},{"key":"2023090107351014000_50.9.1103.53","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023090107351014000_50.9.1103.54","doi-asserted-by":"publisher","DOI":"10.1038\/nri3787"},{"key":"2023090107351014000_50.9.1103.55","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.14"},{"key":"2023090107351014000_50.9.1103.56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.10.1777"},{"key":"2023090107351014000_50.9.1103.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3263"},{"key":"2023090107351014000_50.9.1103.58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.5.1655"},{"key":"2023090107351014000_50.9.1103.59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4465"},{"key":"2023090107351014000_50.9.1103.60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1746"},{"key":"2023090107351014000_50.9.1103.61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2074"},{"key":"2023090107351014000_50.9.1103.62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092695"},{"key":"2023090107351014000_50.9.1103.63","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00126-1"},{"key":"2023090107351014000_50.9.1103.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.02.007"},{"key":"2023090107351014000_50.9.1103.65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003349"},{"key":"2023090107351014000_50.9.1103.66","doi-asserted-by":"crossref","first-page":"622306","DOI":"10.3389\/fimmu.2021.622306","article-title":"The role of natural killer cells in autoimmune diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front Immunol"},{"key":"2023090107351014000_50.9.1103.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.015"},{"key":"2023090107351014000_50.9.1103.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.09.016"},{"key":"2023090107351014000_50.9.1103.69","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02470-6"},{"key":"2023090107351014000_50.9.1103.70","doi-asserted-by":"publisher","DOI":"10.1002\/art.23035"},{"key":"2023090107351014000_50.9.1103.71","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/art.39149","article-title":"Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus","volume":"67","author":"Mohan","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.72","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.41518","article-title":"Modulation of cardiometabolic disease markers by Type I interferon inhibition in systemic lupus erythematosus","volume":"73","author":"Casey","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.73","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001993"},{"key":"2023090107351014000_50.9.1103.74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037000"},{"key":"2023090107351014000_50.9.1103.75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190459"},{"key":"2023090107351014000_50.9.1103.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.10.005"},{"key":"2023090107351014000_50.9.1103.77","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjq023"},{"key":"2023090107351014000_50.9.1103.78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501684"},{"key":"2023090107351014000_50.9.1103.79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0000000000000564","article-title":"Sex bias in autoimmunity","volume":"31","author":"Billi","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2023090107351014000_50.9.1103.80","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142317"},{"key":"2023090107351014000_50.9.1103.81","doi-asserted-by":"publisher","DOI":"10.1002\/art.23701"},{"key":"2023090107351014000_50.9.1103.82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2016.04.002","article-title":"Klinefelter\u2019s syndrome (47,XXY) is in excess among men with Sj\u00f6gren\u2019s syndrome","volume":"168","author":"Harris","year":"2016","journal-title":"Clin Immunol"},{"key":"2023090107351014000_50.9.1103.83","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.39560","article-title":"X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXX in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome","volume":"68","author":"Liu","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.84","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/acr2.11413","article-title":"47XXY and 47XXX in scleroderma and myositis","volume":"4","author":"Scofield","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2023090107351014000_50.9.1103.85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2282-0"},{"key":"2023090107351014000_50.9.1103.86","doi-asserted-by":"publisher","DOI":"10.1038\/nature03479"},{"key":"2023090107351014000_50.9.1103.87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303400"},{"key":"2023090107351014000_50.9.1103.88","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/mst148"},{"key":"2023090107351014000_50.9.1103.89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.12.006"},{"key":"2023090107351014000_50.9.1103.90","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3643"},{"key":"2023090107351014000_50.9.1103.91","doi-asserted-by":"crossref","first-page":"e127291","DOI":"10.1172\/jci.insight.127291","article-title":"The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity","volume":"4","author":"Billi","year":"2019","journal-title":"JCI Insight"},{"key":"2023090107351014000_50.9.1103.92","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/1873-3468.13911","article-title":"Immunometabolic function of the transcription cofactor VGLL3 provides an evolutionary rationale for sexual dimorphism in autoimmunity","volume":"594","author":"Pagenkopf","year":"2020","journal-title":"FEBS Lett"},{"key":"2023090107351014000_50.9.1103.93","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.94","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00848.x"},{"key":"2023090107351014000_50.9.1103.95","doi-asserted-by":"publisher","DOI":"10.1002\/art.22928"},{"key":"2023090107351014000_50.9.1103.96","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"2023090107351014000_50.9.1103.97","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139949"},{"key":"2023090107351014000_50.9.1103.98","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/rheumatology\/key386","article-title":"The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients","volume":"58","author":"Ono","year":"2019","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.99","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023090107351014000_50.9.1103.101","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin Type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023090107351014000_50.9.1103.102","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"2023090107351014000_50.9.1103.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.06.006"},{"key":"2023090107351014000_50.9.1103.104","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of Type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"key":"2023090107351014000_50.9.1103.105","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2023090107351014000_50.9.1103.106","doi-asserted-by":"publisher","DOI":"10.1002\/art.24936"},{"key":"2023090107351014000_50.9.1103.107","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.61"},{"key":"2023090107351014000_50.9.1103.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.011"},{"key":"2023090107351014000_50.9.1103.109","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.110","doi-asserted-by":"crossref","first-page":"23146","DOI":"10.1038\/s41598-021-02522-6","article-title":"Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease","volume":"11","author":"Kuriyama","year":"2021","journal-title":"Sci Rep"},{"key":"2023090107351014000_50.9.1103.111","doi-asserted-by":"crossref","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2023090107351014000_50.9.1103.112","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.42050","article-title":"Identification of similarities between skin lesions in patients with antisynthetase syndrome and skin lesions in patients with dermatomyositis by highly multiplexed imaging mass cytometry","volume":"74","author":"Patel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.113","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","article-title":"MDA5+ dermatomyositis is associated with stronger skin Type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript","volume":"140","author":"Cassius","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023090107351014000_50.9.1103.114","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.20"},{"key":"2023090107351014000_50.9.1103.115","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201381"},{"key":"2023090107351014000_50.9.1103.116","doi-asserted-by":"publisher","DOI":"10.1002\/art.21006"},{"key":"2023090107351014000_50.9.1103.117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510837103"},{"key":"2023090107351014000_50.9.1103.118","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222728"},{"key":"2023090107351014000_50.9.1103.119","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-022-02860-4","article-title":"The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (NETs) in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"24","author":"Peng","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2023090107351014000_50.9.1103.120","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.07.002"},{"key":"2023090107351014000_50.9.1103.122","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063412"},{"key":"2023090107351014000_50.9.1103.123","doi-asserted-by":"crossref","first-page":"8830","DOI":"10.1038\/s41598-020-63757-3","article-title":"Novel biomarkers of a peripheral blood interferon signature associated with drug-na\u00efve early arthritis patients distinguish persistent from self-limiting disease course","volume":"10","author":"Seyhan","year":"2020","journal-title":"Sci Rep"},{"key":"2023090107351014000_50.9.1103.124","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086421"},{"key":"2023090107351014000_50.9.1103.125","doi-asserted-by":"publisher","DOI":"10.1002\/art.27294"},{"key":"2023090107351014000_50.9.1103.126","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaci.2017.08.026","article-title":"The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy","volume":"141","author":"Cooles","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023090107351014000_50.9.1103.127","doi-asserted-by":"publisher","DOI":"10.1186\/ar3819"},{"key":"2023090107351014000_50.9.1103.128","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0564-y"},{"key":"2023090107351014000_50.9.1103.129","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208001"},{"key":"2023090107351014000_50.9.1103.130","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.014"},{"key":"2023090107351014000_50.9.1103.131","doi-asserted-by":"publisher","DOI":"10.1002\/art.21031"},{"key":"2023090107351014000_50.9.1103.132","doi-asserted-by":"publisher","DOI":"10.1002\/art.30187"},{"key":"2023090107351014000_50.9.1103.133","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215571"},{"key":"2023090107351014000_50.9.1103.134","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa167"},{"key":"2023090107351014000_50.9.1103.135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2023090107351014000_50.9.1103.136","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.137","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2727"},{"key":"2023090107351014000_50.9.1103.138","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124466"},{"key":"2023090107351014000_50.9.1103.139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442"},{"key":"2023090107351014000_50.9.1103.140","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei244"},{"key":"2023090107351014000_50.9.1103.141","doi-asserted-by":"publisher","DOI":"10.1002\/art.22382"},{"key":"2023090107351014000_50.9.1103.142","doi-asserted-by":"publisher","DOI":"10.1002\/art.23451"},{"key":"2023090107351014000_50.9.1103.143","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150326"},{"key":"2023090107351014000_50.9.1103.144","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01654.x"},{"key":"2023090107351014000_50.9.1103.145","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.188"},{"key":"2023090107351014000_50.9.1103.146","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207392"},{"key":"2023090107351014000_50.9.1103.147","doi-asserted-by":"publisher","DOI":"10.1002\/art.37742"},{"key":"2023090107351014000_50.9.1103.148","doi-asserted-by":"publisher","DOI":"10.1002\/art.27224"},{"key":"2023090107351014000_50.9.1103.149","doi-asserted-by":"publisher","DOI":"10.1002\/art.27220"},{"key":"2023090107351014000_50.9.1103.150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004005"},{"key":"2023090107351014000_50.9.1103.151","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.152","doi-asserted-by":"crossref","first-page":"e20221085","DOI":"10.1084\/jem.20221085","article-title":"Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses","volume":"219","author":"Chaudhary","year":"2022","journal-title":"J Exp Med"},{"key":"2023090107351014000_50.9.1103.153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam8458"},{"key":"2023090107351014000_50.9.1103.154","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.155","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"2023090107351014000_50.9.1103.156","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"2023090107351014000_50.9.1103.157","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2023090107351014000_50.9.1103.158","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket413"},{"key":"2023090107351014000_50.9.1103.159","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"2023090107351014000_50.9.1103.160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"2023090107351014000_50.9.1103.161","unstructured":"Werth V , Karnell J , Rees W , Targeting plasmacytoid dendritic cells improves cutaneous lupus erythematosus skin lesions and reduces type I interferon levels: results of a phase 1 study of VIB7734 [Abstract]. Arthritis Rheumatol 2020;72 Suppl 10."},{"key":"2023090107351014000_50.9.1103.162","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"},{"key":"2023090107351014000_50.9.1103.163","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"2023090107351014000_50.9.1103.164","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2023090107351014000_50.9.1103.165","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221163"},{"key":"2023090107351014000_50.9.1103.166","unstructured":"Eli Lilly and Company . Updates on OLUMIANT\u00ae (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis. [Internet. Accessed June 15, 2023.] Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/updates-olumiantr-baricitinib-phase-3-lupus-program-and-fda"},{"key":"2023090107351014000_50.9.1103.167","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2023090107351014000_50.9.1103.168","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.5020a"},{"key":"2023090107351014000_50.9.1103.169","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023090107351014000_50.9.1103.170","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.171","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.009"},{"key":"2023090107351014000_50.9.1103.172","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"2023090107351014000_50.9.1103.173","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2023090107351014000_50.9.1103.174","doi-asserted-by":"publisher","DOI":"10.1186\/ar3895"},{"key":"2023090107351014000_50.9.1103.175","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202322"},{"key":"2023090107351014000_50.9.1103.176","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.177","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib, and tirabrutinib in Sj\u00f6gren\u2019s syndrome: randomised, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"2023090107351014000_50.9.1103.178","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"2023090107351014000_50.9.1103.179","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000284"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2022-0827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T02:01:33Z","timestamp":1702692093000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2022-0827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":179,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.3899\/jrheum.2022-0827"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2022-0827","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}